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Neurologically asymptomatic cerebral
oligometastatic prostate carcinoma
metastasis identified on [Ga]Ga-THP-PSMA
PET/CT
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Abstract
Background: Brain metastases from prostate cancer are rare and usually only occur in the context of widespread
systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intact prostate
cancer patient with no other systemic disease, detected using [68Ga]Ga-THP-PSMA PET/CT and only the second one
using a PSMA-based radiopharmaceutical.
Case presentation: We report the case of a prostate cancer patient presenting 5 years after robot-assisted
laparoscopic prostatectomy with biochemical recurrence, no neurological symptoms, and in the absence of
metastatic lesions in the body on conventional imaging. A solitary cerebral metastasis was detected using [68Ga]Ga-
THP-PSMA PET/CT, surgically resected, leading to a drop in serum PSA and a good recovery.
Conclusion: In this case, [68Ga]Ga-THP-PSMA PET/CT resulted in a major change in clinical management and
avoided additional morbidity associated with delayed diagnosis and treatment. This report demonstrates the
importance of considering the presence of metastatic disease outside the conventional locations of prostate cancer
spread, as well as the importance of ensuring comprehensive [68Ga]Ga-PSMA PET/CT coverage from vertex to upper
thighs.
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Background
Prostate cancer usually metastasises to the pelvic lymph
nodes and axial skeleton. Prostate cancer brain metasta-
ses mostly present in the late stages of disease and occur
in an estimated 0.63% of patients [1]. The incidence of
brain-only metastases in prostate cancer, in the absence
of widespread metastatic disease, has been estimated
from large cohorts of patients at 0.0061–0.2% [1–3].
Due to the low incidence of cerebral metastatic disease,
cross-sectional neurological imaging is not routinely per-
formed in prostate cancer patients and PET/CTs using
PSMA-based radiopharmaceuticals are protocoled to
cover the body from skull base to proximal thighs [4, 5].
Twenty-one case reports of solitary brain metastases
from prostate cancer were found in the literature, sum-
marised in Table 1 [6–21], adapted from Barakat et al.
(2016) [17].
Case presentation
A 62-year old male patient had a robot-assisted laparo-
scopic prostatectomy in August 2014 for a Gleason 4 +
3 multifocal adenocarcinoma with tertiary grade 5
disease and extraprostatic extension (pT3aN0Mx). The
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pre-operative PSA was 5.3 μg/L and the post-operative
PSA was unchanged at 5.63 μg/L, despite negative surgi-
cal margins (Fig. 1). The PSA, 6 months post-
operatively, had increased to 10.06 μg/L. Pelvic MRI
showed no local recurrence or residual prostatic tissue
and a bone scan was also negative. Androgen
deprivation therapy (ADT) was commenced with a sub-
sequent fall in PSA to < 0.02 μg/L, but it was discontin-
ued after a year due to side effects.
Serum PSA tests were undertaken regularly (Fig. 1).
4.5 years post-operatively, the PSA increased to 2.33 μg/
L and staging CT and whole-body bone scintigram
showed no evidence of metastatic disease.
Five years after prostatectomy, the PSA reached 10.6
μg/L, and the patient underwent a [68Ga]Ga-THP-PSMA
PET/CT using a cold kit PSMA formulation [22–25].
Sixty minutes after intravenous injection of 204 MBq of
tracer a [68Ga]Ga-THP-PSMA PET/CT was acquired
from proximal thighs to skull base on a GE Discovery
690 PET-CT scanner (GE Healthcare, Chicago, USA) ac-
cording to current guidelines [5] (4 min per bed position
with 23% overlap and axial field of view of 16 cm). A
Table 1 Literature summary of intracranial metastatic prostate cancer case reports without systemic disease
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low-dose unenhanced CT scan (120 kVp, 0.5 s rotation
time, 3.75 mm slices, Noise Index 45, 10–180 mA) was
performed for attenuation correction and localization
purposes. PET reconstructions included corrections for
radiotracer decay, attenuation, modeled scatter, randoms
and dead-time, both for time-of-flight (TOF ordered
subset expectation maximisation with 24 subsets and 2
iterations) and scatter-limit correction series. The PET/
CT showed increased focal uptake in the right mid-
cranial fossa, with no focal uptake in the rest of the
body. The differential considered at this point was a
meningioma, glioma or a prostate metastasis, all known
to express PSMA [26–29]. The patient had no neuro-
logical symptoms at the time of presentation.
A subsequent contrast-enhanced MRI head showed a
well-demarcated enhancing dural-based lesion in the
floor of the right middle cranial fossa, projecting into
the right temporal lobe, with surrounding T2 hyperin-
tense changes in the right temporal lobe, believed to be
extra-axial on MRI. The lesion was thought initially to
represent a meningioma, both on the [68Ga]Ga-THP-
PSMA PET/CT (SUVmax TOF = 6.2) and contrast-
enhanced MRI, although the PET/CT had raised the
suspicion of a prostate cancer metastasis given its un-
usually intense uptake (Fig. 2).
As uncertainty remained between the two possible
diagnoses (meningioma or prostate cancer metastasis) in
the neuro-oncology multidisciplinary team meeting, the
patient was referred for a neurosurgical opinion, which
advised the lesion’s surgical resection and dexametha-
sone 4 mg bd, to reduce surrounding oedema. A second
MRI head, performed 1 month later for pre-surgical
planning, confirmed a 23 × 18 mm solitary tumour with
surrounding oedema in the anterior part of the right
inferior temporal gyrus. The tumour contained hetero-
geneous low and high areas of T2 signal, patchy hetero-
geneous contrast enhancement and dural extension to
the brain surface inferiorly. The second MRI suggested
that the lesion was intra-axial. The contrast-enhanced
post-operative MRI head showed complete resection of
the tumour with a reduction in serum PSA to 2.93 μg/L.
The histopathology report confirmed an intra-axial right
temporal lobe metastatic prostatic adenocarcinoma with
dural extension and intense PSA and PSAP staining.
Three months after neurosurgery the patient had recov-
ered well with only mild neurological deficit (left foot
drop). Surveillance MRI showed no intracranial mass or
abnormal contrast enhancement to indicate residual or
recurrent tumour and only expected post-operative
encephalomalacia in the anterior inferior part of the
right temporal lobe. The serum PSA remained elevated
(2.28 μg/l). Currently, the patient is followed up with 3-
monthly MRIs and PSA monitoring. ADT has not been
restarted. Although the post-operative MRI head showed
complete resection, the fact that histopathology docu-
mented dural involvement could explain the elevated
Fig. 1 Serum PSA, with procedures, over time. Top: serum PSA (μg/L) over time (values of < 0.02 μg/L are plotted as 0 μg/L); bottom: procedures
over time
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PSA after surgery and potential presence of residual
microscopic meningeal disease. The patient is currently
asymptomatic, but he will undergo further PSMA PET/
CT if the PSA continues to rise.
Discussion
This is the first case report of a solitary brain oligome-
tastasis in a neurologically intact prostate cancer patient
with no other systemic disease using [68Ga]Ga-THP-
PSMA PET/CT and only the second one using a PSMA-
based radiopharmaceutical [19]. Current guidelines for
[68Ga]Ga-PSMA PET in prostate cancer patients recom-
mend skull base to proximal thighs coverage [5], which
may result in brain or skull metastases located more cra-
nially remaining undetected. In our case, the solitary
brain metastasis was only seen on the most cranial PET
slices, and, left undiagnosed, would have further in-
creased in size until neurological symptoms became ap-
parent, resulting in delayed treatment and increased
morbidity. Our report illustrates the need to consider
the presence of metastatic disease outside the conven-
tional locations of prostate cancer in patients with per-
sistent or rising PSA and negative conventional imaging.
The other case report, from Yin et al. (2019), describes
a clinical situation remarkably similar to ours [19]. Both
report asymptomatic patients who presented with a rise
in serum PSA, after having previously undergone radical
prostatectomy for Gleason grade 4 + 3 = 7 prostate
adenocarcinoma. Both patients were subsequently found
to have a cerebral metastasis in the right temporal lobe,
although the patient in Yin et al. (2019) also had a
smaller metastasis in the left occipital lobe.
The use of [68Ga]Ga-PSMA PET/CT played a crucial
role in the management of these patients and led to de-
tection and treatment of their disease. A recent study
[30] found that in patients with biochemical recurrence
and in the absence of radiological evidence of metastatic
disease on CT or bone scan [68Ga]Ga-PSMA PET/CT
may lead to a change in management for up to 96% of
patients. Although this study is limited by a small num-
ber (33) of patients, the results are nonetheless impres-
sive. For our patient, the [68Ga]Ga-THP-PSMA PET/CT
resulted in a major change in management (surgical re-
section) and prevented a delayed presentation with
neurological symptoms, systemic (including further
intracranial) metastatic disease, emergency neurosurgery
and increased morbidity.
Conclusion
This is the first documented case of a solitary cerebral
metastasis from prostate cancer in the absence of sys-
temic disease being diagnosed using [68Ga]Ga-THP-
PSMA PET/CT. It demonstrates the usefulness of this
relatively new imaging modality in the investigation and
staging of prostate cancer, as well as the importance of
ensuring comprehensive, vertex-to-thighs, coverage
when performing a [68Ga]Ga-PSMA PET study in pa-
tients with high suspicion of prostate cancer metastases.
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